Table 3. Adverse events.

Events	Placebo (n = 25)	Autologous total IgG (n = 26)
Total No. of adverse events	32	19
Patients with 1 ≥ adverse event	18 (72.0)	13 (50.0)
Patients with 1 ≥ serious adverse event	0	0
Patients with an adverse event leading to withdrawal from intervention	0	0
Exacerbation of atopic dermatitis	12 (48.0)	3 (11.5)
Nasopharyngitis	4 (16.0)	3 (11.5)
Bacterial skin infection	4 (16.0)	3 (11.5)
Upper respiratory tract infection	3 (12.0)	2 (7.7)
Headache	2 (8.0)	1 (3.8)
Eczema herpeticum	2 (8.0)	0
Herpes simplex	1 (4.0)	1 (3.8)
Urticaria	1 (4.0)	0
Conjunctivitis	1 (4.0)	0
Diarrhea	1 (4.0)	0
Myringitis	1 (4.0)	0
Nasal congestion	0	1 (3.8)
Injection-site reaction	0	5 (19.2)

Data are presented as number (%).

IgG, immunoglobulin G.